论文部分内容阅读
目的探讨乙型肝炎病毒(HBV)基因B和C型与阿德福韦酯的疗效关系。方法选取应用阿德福韦酯10mg/d进行抗病毒治疗12、24、36、48周的136例慢性乙型肝炎患者作为研究对象,用聚合酶链反应(PCR)-微板核酸杂交-酶联免疫吸附试验(ELISA)法检测分析基因型,评价阿德福韦酯治疗不同基因型HBV的疗效。结果 136份样本中,HBV基因B型39份,HBV基因C型97份。在治疗12、24、36、48周时,B基因型患者丙氨酸氨基转移酶(ALT)的变化、血清HBVDNA水平下降比例≥2log10及完全抑制情况与C基因型患者相比差异均无统计学意义(P>0.05)。结论本研究所观察的样本中,阿德福韦酯的抗病毒疗效与HBV基因B型和C型均无相关性。
Objective To investigate the relationship between hepatitis B virus (HBV) genes B and C and adefovir dipivoxil. Methods A total of 136 patients with chronic hepatitis B who were treated with adefovir dipivoxil 10 mg / d for 12, 24, 36 and 48 weeks were enrolled in this study. Polymerase chain reaction (PCR) - microplate nucleic acid hybridization - The genotypes were detected by ELISA, and the efficacy of adefovir dipivoxil in treating HBV with different genotypes was evaluated. Results Among the 136 samples, 39 were HBV genotype B and 97 were HBV genotype C, respectively. At 12, 24, 36 and 48 weeks of treatment, there was no statistical difference in the changes of alanine aminotransferase (ALT), serum HBVDNA level in patients with B genotype≥2log10 and complete suppression compared with those in C genotype Significance (P> 0.05). Conclusions The anti-viral efficacy of adefovir dipivoxil in the samples observed in this study was not related to HBV genotypes B and C.